These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 29653858)

  • 21. A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease.
    Goldberg DF; Malhotra RP; Schechter BA; Justice A; Weiss SL; Sheppard JD
    Ophthalmology; 2019 Sep; 126(9):1230-1237. PubMed ID: 30965064
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).
    Holland EJ; Luchs J; Karpecki PM; Nichols KK; Jackson MA; Sall K; Tauber J; Roy M; Raychaudhuri A; Shojaei A
    Ophthalmology; 2017 Jan; 124(1):53-60. PubMed ID: 28079022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Corneal Staining in Patients With Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and Phase 3 Studies.
    Malhotra R; Devries DK; Luchs J; Kabat A; Schechter BA; Shen Lee B; Shettle L; Smyth-Medina R; Ogundele A; Darby C; Bacharach J; Karpecki P
    Cornea; 2019 Oct; 38(10):1259-1265. PubMed ID: 31306284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NOVATIVE: A Phase II/III, Multicenter, Double-masked, Randomized Study of Cyclosporine A 0.05% and 0.1% Ophthalmic Cationic Emulsion Versus Vehicle in Patients with Vernal Keratoconjunctivitis.
    Leonardi A; Pisella PJ; Benítez-Del-Castillo JM; Amrane M; Ismail D; Doan S; Bremond-Gignac D
    Clin Ther; 2023 Dec; 45(12):1284-1288. PubMed ID: 37872059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjunctive Oral Voriconazole Treatment of Fusarium Keratitis: A Secondary Analysis From the Mycotic Ulcer Treatment Trial II.
    Prajna NV; Krishnan T; Rajaraman R; Patel S; Shah R; Srinivasan M; Devi L; Das M; Ray KJ; O'Brien KS; Oldenburg CE; McLeod SD; Zegans ME; Acharya NR; Lietman TM; Rose-Nussbaumer J;
    JAMA Ophthalmol; 2017 Jun; 135(6):520-525. PubMed ID: 28426856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group.
    Stevenson D; Tauber J; Reis BL
    Ophthalmology; 2000 May; 107(5):967-74. PubMed ID: 10811092
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and instrumental assessment of the corneal healing in moderate and severe neurotrophic keratopathy treated with rh-NGF (Cenegermin).
    Roszkowska AM; Inferrera L; Aragona E; Gargano R; Postorino EI; Aragona P
    Eur J Ophthalmol; 2022 Nov; 32(6):3402-3410. PubMed ID: 35473440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of recombinant human nerve growth factor treatment on corneal nerve regeneration in patients with neurotrophic keratopathy.
    Balbuena-Pareja A; Bogen CS; Cox SM; Hamrah P
    Front Neurosci; 2023; 17():1210179. PubMed ID: 37965220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Topical Recombinant Human Nerve Growth Factor on Corneal Epithelial Regeneration in Refractory Epithelial Keratopathy.
    Dai X; Tunc U; Zhu X; Karakus S
    Ocul Immunol Inflamm; 2024 Mar; ():1-7. PubMed ID: 38427335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term restoration of corneal sensitivity in neurotrophic keratopathy after rhNGF treatment.
    Di Zazzo A; Varacalli G; Mori T; Coassin M
    Eur J Ophthalmol; 2022 Jan; 32(1):NP15-NP18. PubMed ID: 32854535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Novel Recombination Human Nerve Growth Factor in Healthy Chinese Subjects.
    Shen Q; Zhang M; Jin Y; Di X; Liu R; Wang Z
    CNS Drugs; 2023 Mar; 37(3):231-242. PubMed ID: 36811740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial.
    Chen M; Gong L; Sun X; Xie H; Zhang Y; Zou L; Qu J; Li Y; He J
    J Ocul Pharmacol Ther; 2010 Aug; 26(4):361-6. PubMed ID: 20698799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Topical Fluorometholone Protects the Ocular Surface of Dry Eye Patients from Desiccating Stress: A Randomized Controlled Clinical Trial.
    Pinto-Fraga J; López-Miguel A; González-García MJ; Fernández I; López-de-la-Rosa A; Enríquez-de-Salamanca A; Stern ME; Calonge M
    Ophthalmology; 2016 Jan; 123(1):141-53. PubMed ID: 26520171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.
    Sall K; Stevenson OD; Mundorf TK; Reis BL
    Ophthalmology; 2000 Apr; 107(4):631-9. PubMed ID: 10768324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pediatric Use of Recombinant Human Nerve Growth Factor 20 μg/mL Eye Drops (Cenegermin) for Bilateral Neurotrophic Keratopathy in Congenital Corneal Anesthesia.
    Leto MG; Toro ME; Indemini PE; Fruttero C; Denina M; Dalmazzo C; Sannia A; Vaiano AS
    Cornea; 2021 Feb; 40(2):228-231. PubMed ID: 33201057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study.
    Karpecki P; Depaolis M; Hunter JA; White EM; Rigel L; Brunner LS; Usner DW; Paterno MR; Comstock TL
    Clin Ther; 2009 Mar; 31(3):514-26. PubMed ID: 19393842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease.
    Baudouin C; de la Maza MS; Amrane M; Garrigue JS; Ismail D; Figueiredo FC; Leonardi A
    Eur J Ophthalmol; 2017 Nov; 27(6):678-685. PubMed ID: 28708219
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial.
    Matsumoto Y; Ohashi Y; Watanabe H; Tsubota K;
    Ophthalmology; 2012 Oct; 119(10):1954-60. PubMed ID: 22739038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Topical human recombinant nerve growth factor for stage 1 Neurotrophic Keratitis: Retrospective case series of cenegermin treatment.
    Epitropoulos AT; Weiss JL
    Am J Ophthalmol Case Rep; 2022 Sep; 27():101649. PubMed ID: 35938145
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial.
    Waldman N; Densie IK; Herbison P
    Acad Emerg Med; 2014 Apr; 21(4):374-82. PubMed ID: 24730399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.